# Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects

> **NCT05966272** · PHASE2 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 199 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection Placebo

## Key facts

- **NCT ID:** NCT05966272
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-12
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-09-24
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966272, "Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05966272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*